Overview

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 g HFA-152a in Subjects With Mild to Moderate Asthma

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-03
Target enrollment:
Participant gender:
Summary
This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. We want to make sure both versions of the inhaler work the same way for people with mild to moderate asthma.
Phase:
PHASE2
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Treatments:
norflurane